Postinduction HypotensionINDUCT-MultiNCT07538388
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
A study testing Continuous Norepinephrine Administration in people with Postinduction Hypotension, run by Universitätsklinikum Hamburg-Eppendorf at 4 sites in Germany.
Trial summary
INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Postinduction Hypotension
- What is being tested?
- Continuous Norepinephrine Administration
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 446 participants
- Where
- 4 sitesGermany
- Study dates
- 7 May 2026to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- We will include consenting patients ≥45 years scheduled for elective non-cardiac surgery under general anesthesia with planned continuous intra-arterial blood pressure monitoring with a radial arterial catheter and with at least two of the following risk criteria for developing acute kidney injury:
- Age ≥65 years
- ASA physical status III or IV
- Chronic arterial hypertension
- Diabetes mellitus requiring medication
- Intra-abdominal surgery
- Preoperative renal insufficiency (serum creatinine ≥1.2 mg/dL)
Who cannot join
- Pregnancy
- Cardiac arrhythmia
- History of intracranial hemorrhage or intracranial aneurysm
- Clinical indication for continuous norepinephrine infusion during induction of general anesthesia (e.g., severe aortic valve stenosis, coronary artery disease, or heart failure)
- Patients who are unable to understand, read, and provide informed consent in German
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Germany4 sites, 4 recruiting
- Not yet recruiting
Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin
Berlin
Sascha Treskatsch, MD, +49 30 450 551 522, sascha.treskatsch@charite.de
- Recruiting
Department of Anesthesiology, University Hospital Duesseldorf, Heinrich Heine University Duesseldorf
Düsseldorf
Sebastian Roth, MD, +49 211 81 16253, Sebastian.Roth@med.uni-duesseldorf.de
- Recruiting
Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf
Hamburg
Kristen K Thomsen, MD, +4940741070215, kr.thomsen@uke.de
- Recruiting
Department of Anaesthesiology, University Hospital LMU Munich
München
Agnes Meidert, MD, +49 89 440081065, Agnes.meidert@med.uni-muenchen.de
About this study
Official title: Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension in High-Risk Non-Cardiac Surgery Patients - The Multicenter INDUCT Trial (INDUCT-Multi)
INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients.
Read the detailed description
Hypotension after induction of general anesthesia, referred to as postinduction hypotension, is common in patients having non-cardiac surgery and is associated with acute kidney injury. Risk factors for postinduction hypotension include older age, higher American Society of Anesthesiologists physical status, chronic arterial hypertension - and higher doses of vasodilating anesthetic drugs. It is reasonable to assume that careful anesthetic management can help maintain blood pressure stability and limit postinduction hypotension. Consistent with this assumption, continuous blood pressure monitoring with an arterial catheter during induction of general anesthesia helps clinicians reduce postinduction hypotension - and is thus recommended in non-cardiac surgery patients at risk for hypotension-related complications.
Besides continuous monitoring, anesthesiologists routinely give vasopressors - such as norepinephrine - to maintain blood pressure. Norepinephrine is a fast acting vasopressor with a short half-life and is usually given as repeated manual boluses during induction of general anesthesia. Given as a bolus, it effectively and rapidly increases blood pressure. However, boluses need to be frequently repeated and well-timed to ensure blood pressure stability.
In a single-center randomized trial, we demonstrated that continuous - compared to bolus - administration of norepinephrine during induction of general anesthesia helps maintain blood pressure stability in high-risk non cardiac surgery patients. We now aim to test the hypothesis that continuous - compared to bolus - administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients who have continuous blood pressure monitoring with an arterial catheter.
- Conditions
- Postinduction Hypotension
- Being tested
- Continuous Norepinephrine Administration
- Keywords
- postinduction hypotension, non-cardiac surgery, norepinephrine, bolus, hypotension, continuous
- Medical subject headings
- Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuous Norepinephrine AdministrationProcedure or surgery
In patients assigned to continuous administration of norepinephrine, a syringe infusion pump will be prepared and connected to a peripheral or central venous catheter. The responsible anesthesiologist will start the norepinephrine infusion and adjust the infusion rate as necessary and may administer additional norepinephrine boluses via the syringe infusion pump if required.
| Study group | Role | What they receive |
|---|---|---|
| Continuous Norepinephrine Administration | Experimental | In patients assigned to continuous norepinephrine administration, norepinephrine will be administered continuously via a syringe infusion pump. Receives: Procedure: Continuous Norepinephrine Administration |
| Bolus Norepinephrine Administration | No intervention | In patients assigned to manual bolus norepinephrine administration, norepinephrine will be given manually in bolus doses. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area under a mean arterial pressure (MAP) of 65 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Secondary outcomes (32)
Area under a MAP of 60 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area under a MAP of 50 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area under a MAP of 40 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 100 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 110 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 120 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 140 mmHg (mmHg x min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <65 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <60 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <50 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <40 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >100 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >110 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >120 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >140 mmHg (min)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <65 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <60 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <50 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <40 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >100 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >110 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >120 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >140 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <65 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <60 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <50 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <40 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >100 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >110 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >120 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >140 mmHg
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Cumulative dose of norepinephrine indexed to body weight (µg kg-1)
Measured: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2026
- Study start7 May 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postinduction HypotensionStudies of the same condition, open and under way.
- More trials run by Universitätsklinikum Hamburg-EppendorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 446 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kristen Thomsen, Universitätsklinikum Hamburg-Eppendorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07538388
- Sponsor's protocol ID
- 2025-101645-BO-ff
- Other IDs
- 2025
- Acronym
- INDUCT-Multi
- Status last verified
- Jun 2026
- First submitted
- 31 Mar 2026
- Last updated
- 29 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension in High-Risk Non-Cardiac Surgery Patients - The Multicenter INDUCT Trial (INDUCT-Multi)
- ClinicalTrials.gov ID
- NCT07538388
- Acronym / sponsor ID
- INDUCT-Multi / 2025-101645-BO-ff
- Conditions
- Postinduction Hypotension
- Keywords
- postinduction hypotension, non-cardiac surgery, norepinephrine, bolus, hypotension, continuous
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 446 participants (estimated)
- Lead sponsor
- Universitätsklinikum Hamburg-EppendorfUniversity, hospital or other
- Study start
- 7 May 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 20 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
INDUCT-Multi is a multicenter randomized trial investigating whether continuous, compared to bolus, administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients.
Detailed description
Hypotension after induction of general anesthesia, referred to as postinduction hypotension, is common in patients having non-cardiac surgery and is associated with acute kidney injury. Risk factors for postinduction hypotension include older age, higher American Society of Anesthesiologists physical status, chronic arterial hypertension - and higher doses of vasodilating anesthetic drugs. It is reasonable to assume that careful anesthetic management can help maintain blood pressure stability and limit postinduction hypotension. Consistent with this assumption, continuous blood pressure monitoring with an arterial catheter during induction of general anesthesia helps clinicians reduce postinduction hypotension - and is thus recommended in non-cardiac surgery patients at risk for hypotension-related complications.
Besides continuous monitoring, anesthesiologists routinely give vasopressors - such as norepinephrine - to maintain blood pressure. Norepinephrine is a fast acting vasopressor with a short half-life and is usually given as repeated manual boluses during induction of general anesthesia. Given as a bolus, it effectively and rapidly increases blood pressure. However, boluses need to be frequently repeated and well-timed to ensure blood pressure stability.
In a single-center randomized trial, we demonstrated that continuous - compared to bolus - administration of norepinephrine during induction of general anesthesia helps maintain blood pressure stability in high-risk non cardiac surgery patients. We now aim to test the hypothesis that continuous - compared to bolus - administration of norepinephrine during induction of general anesthesia reduces postinduction hypotension in high-risk non-cardiac surgery patients who have continuous blood pressure monitoring with an arterial catheter.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Continuous Norepinephrine Administration | Experimental | Procedure: Continuous Norepinephrine AdministrationIn patients assigned to continuous norepinephrine administration, norepinephrine will be administered continuously via a syringe infusion pump. |
| Bolus Norepinephrine Administration | No intervention | –In patients assigned to manual bolus norepinephrine administration, norepinephrine will be given manually in bolus doses. |
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- We will include consenting patients ≥45 years scheduled for elective non-cardiac surgery under general anesthesia with planned continuous intra-arterial blood pressure monitoring with a radial arterial catheter and with at least two of the following risk criteria for developing acute kidney injury:
- Age ≥65 years
- ASA physical status III or IV
- Chronic arterial hypertension
- Diabetes mellitus requiring medication
Key exclusion criteria (5 listed)
- Pregnancy
- Cardiac arrhythmia
- History of intracranial hemorrhage or intracranial aneurysm
- Clinical indication for continuous norepinephrine infusion during induction of general anesthesia (e.g., severe aortic valve stenosis, coronary artery disease, or heart failure)
- Patients who are unable to understand, read, and provide informed consent in German
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuous Norepinephrine AdministrationIn patients assigned to continuous administration of norepinephrine, a syringe infusion pump will be prepared and connected to a peripheral or central venous catheter. The responsible anesthesiologist will start the norepinephrine infusion and adjust the infusion rate as necessary and may administer additional norepinephrine boluses via the syringe infusion pump if required. | Procedure or surgery | Continuous Norepinephrine Administration |
Primary outcome
Area under a mean arterial pressure (MAP) of 65 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
32 secondary outcomes
Area under a MAP of 60 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area under a MAP of 50 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area under a MAP of 40 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 100 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 110 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 120 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Area above a MAP of 140 mmHg (mmHg x min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <65 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <60 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <50 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP <40 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >100 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >110 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >120 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Duration of a MAP >140 mmHg (min)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <65 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <60 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <50 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement <40 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >100 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >110 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >120 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with any MAP measurement >140 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <65 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <60 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <50 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP <40 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >100 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >110 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >120 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Absolute (n) and relative (%) number of patients with at least one 1-minute episode of a MAP >140 mmHg
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Cumulative dose of norepinephrine indexed to body weight (µg kg-1)
Time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Postinduction Hypotension
Not yet recruitingObservational study
SV and IVC Collapsibility Index to Predict Postinduction Hypotension
Post-induction Hypotension, Intestinal Obstruction
Recruiting
Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension
Postinduction Hypotension
Recruiting
5 Versus 10 mcg Norepinephrine Bolus in Treatment of Postinduction and Early Intraoperative Hypotension in Emergency Abdominal Surgery
Hypotension on Induction, Emergency Surgery
Active, not recruiting
Pre-op Fluid Study
Hypotension Drug-Induced, Anesthesia
Enrolling by invitationPhase 4
The Effect of Preoperative Intravenous Fluid Bolus on Post-induction Hypotension in Elective Cystoscopies.
Postinduction Hypotension, Hypotension During Surgery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuous Norepinephrine Administration in people with Postinduction Hypotension, run by Universitätsklinikum Hamburg-Eppendorf at 4 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kristen K Thomsen, MD (+4940741070215, kr.thomsen@uke.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area under a mean arterial pressure (MAP) of 65 mmHg (mmHg x min) (time frame: First 15 minutes after starting induction of general anesthesia. The start of anesthetic induction is defined as the administration of propofol as hypnotic induction agent.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.